Clinical Trial Update: A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rivaroxaban to reduce major thrombotic events, hospitalization, and death in medically ill outpatients with acute COVID-19; study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Coronavirus Disease 2019 (COVID-19) | Phase 3 | Status: TERMINATED | Results posted: 2023-07-18